What type of study is this?

Clinical outcomes of tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma: insights from a single-center study

View Full Paper

Ask AI

Bookmark

Tisagenlecleucel demonstrated an overall response rate of 71.9% at 1 month, declining to 55.1% at 3 months.
Patients achieving complete remission at 3 months had significantly improved progression-free survival and overall survival.
Cytokine release syndrome occurred in 75% of patients, with manageable grade ≥ 3 adverse events.
Median overall survival was 13.9 months, with a 1-year overall survival rate of 55.2%.

No takes yet. Share an insight, caveat, or question.

Observational analysis shows significant survival benefits of tisagenlecleucel in patients with RR-DLBCL, indicating manageable toxicities.

Yoon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows significant survival benefits of tisagenlecleucel in patients with RR-DLBCL, indicating manageable toxicities.